stocks logo

HCWB Valuation

HCW Biologics Inc
$
4.150
-0.11(-2.582%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

HCWB Relative Valuation

HCWB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HCWB is overvalued; if below, it's undervalued.

Historical Valuation

HCW Biologics Inc (HCWB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.10 is considered Undervalued compared with the five-year average of -3.02. The fair price of HCW Biologics Inc (HCWB) is between 14.25 to 118.10 according to relative valuation methord. Compared to the current price of 4.13 USD , HCW Biologics Inc is Undervalued By 71.02%.
Relative Value
Fair Zone
14.25-118.10
Current Price:4.13
71.02%
Undervalued
-0.77
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
HCW Biologics Inc. (HCWB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.92. The thresholds are as follows: Strongly Undervalued below -3.16, Undervalued between -3.16 and -2.04, Fairly Valued between 0.20 and -2.04, Overvalued between 0.20 and 1.32, and Strongly Overvalued above 1.32. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-2.07
EV/EBIT
HCW Biologics Inc. (HCWB) has a current EV/EBIT of -2.07. The 5-year average EV/EBIT is -3.22. The thresholds are as follows: Strongly Undervalued below -13.42, Undervalued between -13.42 and -8.32, Fairly Valued between 1.88 and -8.32, Overvalued between 1.88 and 6.98, and Strongly Overvalued above 6.98. The current Forward EV/EBIT of -2.07 falls within the Historic Trend Line -Fairly Valued range.
1.10
PS
HCW Biologics Inc. (HCWB) has a current PS of 1.10. The 5-year average PS is 276.72. The thresholds are as follows: Strongly Undervalued below -1535.50, Undervalued between -1535.50 and -629.39, Fairly Valued between 1182.83 and -629.39, Overvalued between 1182.83 and 2088.94, and Strongly Overvalued above 2088.94. The current Forward PS of 1.10 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
HCW Biologics Inc. (HCWB) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.24. The thresholds are as follows: Strongly Undervalued below -7.91, Undervalued between -7.91 and -4.58, Fairly Valued between 2.09 and -4.58, Overvalued between 2.09 and 5.42, and Strongly Overvalued above 5.42. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
HCW Biologics Inc. (HCWB) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.43. The thresholds are as follows: Strongly Undervalued below -1.98, Undervalued between -1.98 and -1.20, Fairly Valued between 0.34 and -1.20, Overvalued between 0.34 and 1.11, and Strongly Overvalued above 1.11. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
HCW Biologics Inc (HCWB) has a current Price-to-Book (P/B) ratio of -0.56. Compared to its 3-year average P/B ratio of -0.63 , the current P/B ratio is approximately -11.93% higher. Relative to its 5-year average P/B ratio of -0.16, the current P/B ratio is about 254.38% higher. HCW Biologics Inc (HCWB) has a Forward Free Cash Flow (FCF) yield of approximately -184.72%. Compared to its 3-year average FCF yield of -68.08%, the current FCF yield is approximately 171.33% lower. Relative to its 5-year average FCF yield of -53.43% , the current FCF yield is about 245.72% lower.
-0.56
P/B
Median3y
-0.63
Median5y
-0.16
-184.72
FCF Yield
Median3y
-68.08
Median5y
-53.43

Competitors Valuation Multiple

The average P/S ratio for HCWB's competitors is 15.90, providing a benchmark for relative valuation. HCW Biologics Inc Corp (HCWB) exhibits a P/S ratio of 1.10, which is -93.06% above the industry average. Given its robust revenue growth of -99.55%, this premium appears unsustainable.

Performance Decomposition

1Y
3Y
5Y
Market capitalization of HCWB decreased by 82.82% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -662.82 to -43.37K.
The secondary factor is the Revenue Growth, contributed -99.55%to the performance.
Overall, the performance of HCWB in the past 1 year is driven by Margin Expansion. Which is more sustainable.
-99.55%
1.13M → 5.07K
Revenue Growth
+
6443.80%
-662.82 → -43.37K
Margin Expansion
+
-6427.07%
0.00 → -0.17
P/E Change
=
-82.82%
24.16 → 4.15
Mkt Cap Growth

FAQ

arrow icon

Is HCW Biologics Inc (HCWB) currently overvalued or undervalued?

HCW Biologics Inc (HCWB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.10 is considered Undervalued compared with the five-year average of -3.02. The fair price of HCW Biologics Inc (HCWB) is between 14.25 to 118.10 according to relative valuation methord. Compared to the current price of 4.13 USD , HCW Biologics Inc is Undervalued By 71.02% .
arrow icon

What is HCW Biologics Inc (HCWB) fair value?

arrow icon

How does HCWB's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for HCW Biologics Inc (HCWB) as of Jul 29 2025?

arrow icon

What is the current FCF Yield for HCW Biologics Inc (HCWB) as of Jul 29 2025?

arrow icon

What is the current Forward P/E ratio for HCW Biologics Inc (HCWB) as of Jul 29 2025?

arrow icon

What is the current Forward P/S ratio for HCW Biologics Inc (HCWB) as of Jul 29 2025?